Display options
Cite
Butt J, Blot WJ, Visvanathan K, et al. Auto-antibodies to p53 and the Subsequent Development of Colorectal Cancer in a U.S. Prospective Cohort Consortium. Cancer Epidemiol Biomarkers Prev. 2020;29(12):2729-2734doi: 10.1158/1055-9965.EPI-20-0780.
Butt, J., Blot, W. J., Visvanathan, K., Le Marchand, L., Wilkens, L. R., Chen, Y., Sesso, H. D., Teras, L., Ryser, M. D., Hyslop, T., Wassertheil-Smoller, S., Tinker, L. F., Potter, J. D., Song, M., Berndt, S. I., Waterboer, T., Pawlita, M., & Epplein, M. (2020). Auto-antibodies to p53 and the Subsequent Development of Colorectal Cancer in a U.S. Prospective Cohort Consortium. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 29(12), 2729-2734. https://doi.org/10.1158/1055-9965.EPI-20-0780
Butt, Julia, et al. "Auto-antibodies to p53 and the Subsequent Development of Colorectal Cancer in a U.S. Prospective Cohort Consortium." Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology vol. 29,12 (2020): 2729-2734. doi: https://doi.org/10.1158/1055-9965.EPI-20-0780
Butt J, Blot WJ, Visvanathan K, Le Marchand L, Wilkens LR, Chen Y, Sesso HD, Teras L, Ryser MD, Hyslop T, Wassertheil-Smoller S, Tinker LF, Potter JD, Song M, Berndt SI, Waterboer T, Pawlita M, Epplein M. Auto-antibodies to p53 and the Subsequent Development of Colorectal Cancer in a U.S. Prospective Cohort Consortium. Cancer Epidemiol Biomarkers Prev. 2020 Dec;29(12):2729-2734. doi: 10.1158/1055-9965.EPI-20-0780. Epub 2020 Sep 24. PMID: 32972968; PMCID: PMC7710535.
Copy Download .nbib Format: NLM
Share it on

Cancer Epidemiol Biomarkers Prev. 2020 Dec;29(12):2729-2734. doi: 10.1158/1055-9965.EPI-20-0780. Epub 2020 Sep 24.

Auto-antibodies to p53 and the Subsequent Development of Colorectal Cancer in a U.S. Prospective Cohort Consortium.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

Julia Butt, William J Blot, Kala Visvanathan, Loïc Le Marchand, Lynne R Wilkens, Yu Chen, Howard D Sesso, Lauren Teras, Marc D Ryser, Terry Hyslop, Sylvia Wassertheil-Smoller, Lesley F Tinker, John D Potter, Mingyang Song, Sonja I Berndt, Tim Waterboer, Michael Pawlita, Meira Epplein

Affiliations

  1. Infections and Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. [email protected].
  2. Cancer Control and Population Sciences Program, Duke Cancer Institute, and Department of Population Health Sciences, Duke University, Durham, North Carolina.
  3. Division of Epidemiology, Vanderbilt University Medical Center, Nashville, Tennessee.
  4. Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore, Maryland.
  5. Epidemiology Program, University of Hawai'i Cancer Center, Honolulu, Hawaii.
  6. Department of Population Health, New York University School of Medicine, New York, New York.
  7. Brigham and Women's Hospital, Boston, Massachusetts.
  8. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
  9. Behavioral and Epidemiology Research Group, American Cancer Society, Atlanta, Georgia.
  10. Department of Population Health Sciences, and Department of Mathematics, Duke University, Durham, North Carolina.
  11. Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina.
  12. Department of Epidemiology & Population Health, Albert Einstein College of Medicine, Bronx, New York.
  13. Cancer Prevention Program, Division of Public Health Sciences at Fred Hutchinson Cancer Research Center, Seattle, Washington.
  14. Centre for Public Health Research, Massey University, Wellington, New Zealand.
  15. Fred Hutchinson Cancer Research Center, Seattle, Washington.
  16. Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
  17. Clinical and Translational Epidemiology Unit and Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
  18. Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland.
  19. Infections and Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.

PMID: 32972968 PMCID: PMC7710535 DOI: 10.1158/1055-9965.EPI-20-0780

Abstract

BACKGROUND: Auto-antibodies to tumor suppressor p53 are found in a subset of patients with colorectal cancer. A recent prospective study in the United States has reported a significant 1.8-fold increased odds for colorectal cancer development with prediagnostic seropositivity to p53. In this study, we sought to examine this association in a U.S. colorectal cancer cohort consortium to evaluate the potential utility of p53 auto-antibodies as an early biomarker for colorectal cancer.

METHODS: Auto-antibodies to p53 were measured in prediagnostic blood samples of 3,702 incident colorectal cancer cases and 3,702 controls, matched by age, race, and sex, from 9 U.S. prospective cohorts. The association of seropositivity to p53 with colorectal cancer risk, overall and by time between blood draw and diagnosis, was determined by conditional logistic regression.

RESULTS: Overall, 5% of controls and 7% of cases were seropositive to p53, resulting in a statistically significant 33% increased colorectal cancer risk [odds ratio (OR), 1.33; 95% confidence interval (CI), 1.09-1.61]. By follow-up time, the association was only significant with colorectal cancer diagnoses within 4 years after blood draw (OR, 2.27; 95% CI, 1.62-3.19), but not thereafter (OR, 0.97; 95% CI, 0.76-1.24).

CONCLUSIONS: In this large consortium of prospective cohorts, we found that prediagnostic seropositivity to tumor suppressor p53 was significantly associated with an over 2-fold increased odds of developing colorectal cancer within 4 years after blood draw.

IMPACT: Our finding suggests that p53 seropositivity may not be a useful predictor of long-term colorectal cancer risk; however, it might be considered as a marker to aid in the early diagnosis of colorectal cancer.

©2020 American Association for Cancer Research.

References

  1. Cancer Lett. 2014 May 1;346(2):178-87 - PubMed
  2. Nat Rev Immunol. 2017 Jan;17(1):21-29 - PubMed
  3. Clin Gastroenterol Hepatol. 2015 Aug;13(8):1472-9 - PubMed
  4. Am J Gastroenterol. 2008 Jun;103(6):1541-9 - PubMed
  5. Clin Chem. 2005 Oct;51(10):1845-53 - PubMed
  6. CA Cancer J Clin. 2017 May 6;67(3):177-193 - PubMed
  7. Oncotarget. 2016 Mar 29;7(13):16420-32 - PubMed
  8. Gastroenterology. 2019 Jan;156(1):175-186.e2 - PubMed
  9. Clin Gastroenterol Hepatol. 2019 Aug;17(9):1829-1839.e4 - PubMed
  10. Eur J Cancer Prev. 1999 Dec;8 Suppl 1:S39-47 - PubMed
  11. Cancer Res. 1990 Dec 1;50(23):7717-22 - PubMed
  12. Oncol Lett. 2018 Apr;15(4):5489-5496 - PubMed
  13. Cancer Res. 2000 Apr 1;60(7):1777-88 - PubMed
  14. Clin Cancer Res. 2016 Apr 1;22(7):1725-33 - PubMed
  15. Cancer Epidemiol Biomarkers Prev. 2018 Oct;27(10):1186-1194 - PubMed
  16. BMJ. 2014 Apr 09;348:g2467 - PubMed
  17. Nat Rev Gastroenterol Hepatol. 2011 Nov 01;8(12):711-22 - PubMed
  18. Clin Cancer Res. 2001 May;7(5):1118-26 - PubMed
  19. Nat Rev Cancer. 2009 Oct;9(10):701-13 - PubMed
  20. Br J Cancer. 2013 Jan 15;108(1):107-14 - PubMed
  21. Eur J Cancer. 2013 Sep;49(14):3049-54 - PubMed
  22. Cancer Epidemiol Biomarkers Prev. 2018 Feb;27(2):219-223 - PubMed

Publication Types

Grant support